ANTIFOLATE DRUGS IN CANCER THERAPY

Edited by Ann L. JACKMAN

The Cancer Research Campaign Centre for Cancer Therapeutics, The Institute of Cancer Research, Sutton, Surrey, UK



ENT

9

:al

HUMANA PRESS Totowa, New Jersey

Find authenticated court documents without watermarks at docketalarm.com.

© 1999 Humana Press Inc. 999 Riverview Drive, Suite 208 Totowa, New Jersey 07512

All rights reserved.

No part of this book may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, microfilming, recording, or otherwise without written permission from the Publisher.

(

2

Ţ

Ŧ

Т

S

r

ł

f f s F t

All authored papers, comments, opinions, conclusions, or recommendations are those of the author(s), and do not necessarily reflect the views of the publisher.

For additional copies, pricing for bulk purchases, and/or information about other Humana titles, contact Humana at the above address or at any of the following numbers: Tel.: 973-256-1699; Fax: 973-256-8341; E-mail: humana@humanapr.com

This publication is printed on acid-free paper. ANSI Z39.48-1984 (American Standards Institute) Permanence of Paper for Printed Library Materials.

Cover illustration:

 \bigcirc

Cover design by Patricia F. Cleary.

Photocopy Authorization Policy:

Authorization to photocopy items for internal or personal use, or the internal or personal use of specific clients, is granted by Humana Press Inc., provided that the base fee of US \$5.00 per copy, plus US \$00.25 per page, is paid directly to the Copyright Clearance Center at 222 Rosewood Drive, Danvers, MA 01923. For those organizations that have been granted a photocopy license from the CCC, a separate system of payment has been arranged and is acceptable to Humana Press Inc. The fee code for users of the Transactional Reporting Service is: [0-89603-460-7/97 \$5.00 + \$00.25].

Printed in the United States of America. 10 9 8 7 6 5 4 3 2 1

)yle et al.

Effects of inhibitor

). Phase I

I trial of nuous in-

Preclinical and Clinical Evaluation of the Glycinamide Ribonucleotide Formyltransferase Inhibitors Lometrexol and LY309887

Laurane G. Mendelsohn, John F. Worzalla and Jackie M. Walling

CONTENTS

12

INTRODUCTION INHIBITION OF GARFT AND POLYGLUTAMATION BY FOLYLPOLYGLUTAMATE SYNTHETASE FOLATE-RECEPTOR SELECTIVITY OF ANTIFOLATES CELLULAR PHARMACOLOGY IN VIVO ANTITUMOR ACTIVITY OF LY309887 THERAPEUTIC INDEX DETERMINATIONS THE EFFECT OF DIETARY FOLATE ON DISPOSITION OF LOMETREXOL AND LY309887 IN LIVER THE EFFECT OF LFD AND DIETARY FOLATE SUPPLEMENTATION ON THE EFFICACY AND TOXICITY OF LOMETREXOL AND LY309887 HUMAN FOLATE STATUS CLINICAL EVALUATION OF LOMETREXOL AND LY309887 PHASE I STUDIES WITHOUT FOLIC ACID SUPPLEMENTATION PHASE I STUDIES WITH FOLIC ACID SUPPLEMENTATION PHASE I STUDY OF LOMETREXOL WITH FOLINIC ACID How Does Folic Acid Modulate Toxicity? ANTITUMOR ACTIVITY IN PHASE I **PHARMACOKINETICS** CLINICAL DEVELOPMENT OF LY309887 CONCLUSION REFERENCES

From: Anticancer Drug Development Guide: Antifolate Drugs in Cancer Therapy Edited by: A.L. Jackman © Humana Press Inc., Totowa, NJ

261

1. INTRODUCTION

The importance of the purine de novo pathway in providing DNA precursors for cancer cell growth led to the hypothesis that novel antifolate inhibitors of glycinamide ribonucleotide formyltransferase (GARFT), the first folate-dependent enzyme in this pathway, might have utility in the treatment of cancer. In 1987, clinical investigations were initiated with lometrexol (6R-dideazatetrahydrofolic acid, 6R-DDATHF), a novel "tight-binding" inhibitor of GARFT with potent antitumor activity in a number of murine and human xenograft solid tumors. Unexpected observations of delayed cumulative toxicity in phase I clinical trials prompted extensive preclinical investigations of the dynamics of folate status on the efficacy and toxicity of GARFT inhibitors and other antifolates (1). In addition, structure-activity studies have led to the identification of a second generation GARFT inhibitor, LY309887 (2',5'-thienyl-dideazatetrahydrofolic acid), which is more potent than lometrexol and has greater antitumor efficacy in vivo (2). Biochemical and pharmacological differences between LY309887 and lometrexol with respect to potency to inhibit GARFT, differential transport and storage in liver, and polyglutamation suggest that LY309887 may have greater antitumor efficacy and more manageable toxicity in the clinic than lometrexol. A murine model of the delayed cumulative toxicity seen with lometrexol has been refined and characterized to provide greater understanding of the pharmacokinetics and pharmacodynamics of these events. In concert with recently published nutritional data on the folate status of humans and more sophisticated methods of assessing and modulating antifolate toxicities through vitamin supplementation, antifolate therapy may be poised to enter a new phase of clinical success. In this report, we describe LY309887, a GARFT inhibitor with unique biochemical and pharmacological properties that has antitumor activity against a broad panel of human xenograft tumors, and greater potency than lometrexol both as an inhibitor of GARFT and as an inhibitor of tumor growth in vivo. An overview of the phase I clinical results with lometrexol and the design of the phase I clinical trial with LY309887 will be presented.

2. INHIBITION OF GARFT AND POLYGLUTAMATION BY FOLYLPOLYGLUTAMATE SYNTHETASE

The natural forms of folic acid and "classical" inhibitors of folate-dependent enzymes are polyglutamated intracellularly by the enzyme folylpolyglutamate synthetase. Polyglutamylation enhances both intracellular retention and affinity of folates and antifolates for many of the folate-utilizing enzymes (3). Table 1 summarizes the inhibition of GARFT by lometrexol, compound LY254155 (6R,S-2',5'-thienyl-DDATHF, a diastereoisomeric mix of LY309887 and LY309886, respectively) and their polyglutamates. Monoglutamated LY254155 was approx 30-fold more potent than lometrexol. Polyglutamation enhanced inhibition by both compounds: lometrexol-triglutamate (LY235337) was approx 4.5-fold more potent than parent compound; a 10-fold increase in inhibition was seen with the triglutamated thiophene (LY314209). These data demonstrate that the thiophene was inherently more potent as a GARFT inhibitor and that in the polyglutamated state it achieved picomolar affinity for GARFT.

The kinetic constants ($K_{\rm m}$, $V_{\rm max}$, and first-order rate constant [$V_{\rm max}/K_{\rm nf}$]) for activa-

DOCKE

Find authenticated court documents without watermarks at docketalarm.com.

tior Tat

util (V_m stra obt: a fil FP(cub HPI all s

vert

in u

serv

at h

late

ular

cycl

nom

A

eve

Cł

Chapter 12 / Lometrexol and LY309887

LY314209

Inhibition of hGARFT by Lometrexol, 254155, and Polyglutamates				
Compound No.	Compound Name	$hGARFT K_i (nM)$		
LY249543	lometrexol	59.7 $(n = 2)$		
LY235540	diglu	15.4 (n = 2)		
LY235337	triglu	13.3 (n = 2)		
LY266978	tetraglu	$7.1 \pm 2.2 \ (n=4)$		
LY235542	pentaglu	5.3 (n = 2)		
LY254155	thienyl-DDATHF	$2.1 \pm 0.2 \ (n = 5)$		
LY314565	diglu	1.2(n = 1)		

triglu

Table 1

263

The potency of antifolate analogs to inhibit monofunctional human GARFT was assessed spectrophometrically using the Morrison equation, which is appropriate for determining the affinity of "tight-binding" compounds that produce stoichiometric inhibition (2, 4).

0.25 (n = 2)

Table 2				
Kinetic Constants for Activation of GARFT Inhibitors by FPGS				

Compound	$K_m \left(\mu M \right)$	Vmax (µmoles/h/mg)	$k'(V_m/K_m)$
lometrexol	16.4 ± 1.0	977 ± 128	60
LY309887	6.5 ± 1.1	-686 ± 116	43
MTA	1.9 ± 0.5	725 ± 95	381

tion of lometrexol and LY309887, determined using hog liver FPGS are summarized in Table 2 (5). Lometrexol and LY309887 had similar K_m values as FPGS substrates. However, lometrexol had a significantly higher V_{max} . The relative efficiencies of substrate utilization by an enzyme can be determined by comparing first-order rate constants, k' $(V_{\text{max}}/K_{\text{m}})$. The data suggest that despite equal K_{m} values, lometrexol was a better substrate, which would be more extensively polyglutamated in vivo. For comparison, data obtained with the multitargeted antifolate inhibitor, LY231514 (MTA), is shown. With a first-order rate constant of 381, it clearly had the greatest affinity and efficacy as an FPGS substrate. In other experiments, polyglutamated products formed during a 24-h incubation of lometrexol, LY309887 or MTA with FPGS were separated by quantitative HPLC. At low substrate concentrations, i.e., below the K_m (1 μM), polyglutamation of all substrates was more extensive and a higher percentage of the total product was converted to tetra- and pentaglutamated forms than at high substrate concentrations (20 μ M) in which over 70% of each antifolate was present as the triglutamate analog. These observations are consistent with the known substrate inhibition of FPGS that occurs in vivo at high intracellular folate concentrations (6).

An important inference from these data is that folate-deficient patients may accumulate and retain greater amounts of highly polyglutamated "classical antifolates," particularly in liver, a known folate depot, than patients who are folate-replete. Continuous cycling of stored antifolate through the enterohepatic pathway may explain the phenomenon of delayed and cumulative toxicity in cancer patients on lometrexol and in

Walling

for cannide riin this gations a novel iber of cumuions of d other on of a Irofolic in vivo etrexol er, and d more /ed curovide events. ns and ıgh vif cliniunique broad an inphase 1 with

zymes Polyfolates ion of a diglutarexol. amate crease emonhat in

.ctiva-

DOCKET A L A R M



Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.